Immix Biopharma (IMMX) Price Target Increased to $25 by H.C. Wainwright

H.C. Wainwright has raised the price target for Immix Biopharma (IMMX) to $25. This adjustment reflects the firm's updated outlook on the company's growth potential and market position. A higher price target may influence investor sentiment, potentially leading to increased trading activity around Immix Biopharma's stock. This matters for ordinary investors as it suggests a more favorable view of the company's future performance.